Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
- PMID: 1596900
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
Abstract
Single-chain antigen-binding proteins, or sFvs, represent potentially unique molecules for targeted delivery of drugs, toxins, or radionuclides to a tumor site. In previous studies (Cancer Res., 51:6363-6371, 1991) using a human colon carcinoma xenograft model, it was demonstrated that the sFv has an extremely rapid plasma and whole body clearance, as compared to intact IgG or Ig fragments. One potential consequence of the rapid sFv pharmacokinetic properties was the reduced percentage of injected dose/g of the radiolabeled sFv found in the tumor throughout a range of time points. The present study was designed to define the tumor penetration properties of a radiolabeled sFv in comparison with other Ig forms. 125I-labeled sFv, Fab', F(ab')2, and IgG forms of monoclonal antibody CC49, directed against the human pancarcinoma antigen TAG-72, were used to target the LS-174T human colon carcinoma xenograft in athymic mice. At various time points after systemic Ig administration, quantitative autoradiographic analyses of surgically removed tumors were used to define the rate and degree of penetration of the various Ig forms. These studies revealed that most of the intact IgG delivered to the tumor was concentrated in the region of or immediately adjacent to vessels, while the sFv was more evenly distributed throughout the tumor mass. The distributions of the Fab' and F(ab')2 fragments showed intermediate penetration in a size-related manner. The sFv demonstrated maximum tumor penetration at 0.5 h postinjection, while the intact IgG reached an equivalent degree of penetration at 48 to 96 h postinjection. These studies thus reveal a greater degree of uptake throughout the tumor for the sFv than would be expected by gross analyses of percentage injected dose/g and demonstrate an extremely rapid tumor penetration of the sFv. These studies should aid in the rational design of potential applications of drug-, toxin-, and radionuclide-conjugated sFvs in cancer therapy.
Similar articles
-
Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.Cancer Res. 1993 Aug 15;53(16):3776-83. Cancer Res. 1993. PMID: 8339291
-
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.Cancer Res. 1991 Dec 1;51(23 Pt 1):6363-71. Cancer Res. 1991. PMID: 1933899
-
Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.Clin Cancer Res. 1999 Sep;5(9):2613-9. Clin Cancer Res. 1999. PMID: 10499640
-
Pharmacokinetics and biodistribution of genetically-engineered antibodies.Q J Nucl Med. 1998 Dec;42(4):225-41. Q J Nucl Med. 1998. PMID: 9973838 Review.
-
Radioiodinated anti–TAG-72 CC49 (Fab’)2 antibody fragment.2007 Nov 5 [updated 2008 Jan 9]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Nov 5 [updated 2008 Jan 9]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641775 Free Books & Documents. Review.
Cited by
-
Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents.Neoplasia. 2024 Feb;48:100962. doi: 10.1016/j.neo.2023.100962. Epub 2024 Jan 5. Neoplasia. 2024. PMID: 38183712 Free PMC article.
-
A fully human connective tissue growth factor blocking monoclonal antibody ameliorates experimental rheumatoid arthritis through inhibiting angiogenesis.BMC Biotechnol. 2023 Mar 3;23(1):6. doi: 10.1186/s12896-023-00776-8. BMC Biotechnol. 2023. PMID: 36869335 Free PMC article.
-
Engineering anti-vascular endothelial growth factor single chain disulfide-stabilized antibody variable fragments (sc-dsFv) with phage-displayed sc-dsFv libraries.J Biol Chem. 2010 Mar 12;285(11):7880-91. doi: 10.1074/jbc.M109.061457. Epub 2010 Jan 12. J Biol Chem. 2010. PMID: 20068035 Free PMC article.
-
5th Annual Monoclonal Antibodies Conference: March 24-25, 2009, London, UK.MAbs. 2009 Jul-Aug;1(4):308-17. doi: 10.4161/mabs.1.4.8956. MAbs. 2009. PMID: 20073132 Free PMC article.
-
Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies.Drug Des Devel Ther. 2022 Aug 9;16:2659-2680. doi: 10.2147/DDDT.S378450. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35971530 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources